Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC

Researchers found that at 36 months, the estimated event-free survival was 84.5 and 76.8% in the pembrolizumab-chemotherapy and placebo-chemotherapy groups, respectively.

Related Keywords

Peter Schmid ,Queen Mary University Of London ,Healthday News ,New England Journal ,Queen Mary University ,Merck Sharp ,